stockrow
Friday 6 November 2026
Export ALNY’s income statement to Excel — free account
Alnylam Pharmaceuticals, Inc.
ALNY Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024.
- Revenue
- +16.7%
- EPS
- +747.6%
- Free cash flow
- −4.76%
- Total debt
- −2.66%
Quarter to September 2026, against a year earlier
156.01
0.65
−0.41%
Follow ALNY
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
189.42 | 87.30 | 54.44 | 12.46 |
P/S ratio |
14.16 | 10.26 | 8.37 | 6.59 | |
P/FCF ratio |
112.99 | 68.35 | 49.06 | 40.95 | |
P/Operating CF |
241.50 | 623.66 | 123.10 | 96.84 | |
P/B ratio |
66.63 | 40.89 | 29.70 | 9.16 | |
Price to Tangible BV |
66.63 | 40.89 | 29.70 | 9.16 | |
EV/Sales |
13.65 | 9.79 | 7.89 | 6.07 | |
EV/EBITDA |
90.95 | 52.01 | 35.96 | 29.47 | |
EV/Operating CF |
96.71 | 58.71 | 41.59 | 31.85 | |
EV/FCF |
108.90 | 65.24 | 46.25 | 37.76 | |
Quick Ratio |
2.51 | 2.89 | 2.79 | 2.26 | |
Current Ratio |
2.76 | 3.13 | 3.05 | 2.48 | |
Net Debt/EBITDA |
(13.09) | (7.09) | (9.36) | (7.15) | |
Debt/Assets |
20.29% | 19.68% | 18.19% | 12.67% | |
Debt/Equity |
1.28 | 0.94 | 0.75 | 0.28 | |
Asset Turnover |
0.81 | 0.92 | 0.95 | 0.78 | |
Operating CF/Net income |
1.95 | 0.34 | 1.99 | 0.16 | |
Capex/Depreciation |
(1.72) | (1.61) | (2.50) | (4.82) | |
Interest Coverage |
2.01 | 3.88 | 2.82 | 4.10 | |
Research and Development Expense of Revenue |
33.93% | 31.26% | 32.00% | 28.02% | |
Selling, General and Administrative Expense of Revenue |
29.66% | 27.64% | 26.95% | 23.46% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
6.53% | 6.01% | 6.71% | 5.43% | |
Graham Net Nets |
0.00 | 0.00 | 0.01 | 0.02 | |
Graham Number |
16.79 | 26.27 | 35.51 | 109.56 | |
Earnings Yield |
0.53% | 1.15% | 1.84% | 8.03% | |
Free Cash Flow Yield |
0.89% | 1.46% | 2.04% | 2.44% | |
Revenue per Share |
8.30 | 8.78 | 9.66 | 10.90 | |
Operating CF per Share |
1.65 | 0.53 | 2.45 | 2.55 | |
Capex per Share |
(0.18) | (0.16) | (0.26) | (0.52) | |
Free Cash Flow per Share |
1.47 | 0.37 | 2.19 | 2.03 | |
Cash per Share |
22.00 | 22.64 | 24.76 | 26.81 | |
Shareholders Equity per Share |
5.97 | 8.09 | 10.14 | 26.93 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.97 | 8.09 | 10.14 | 26.93 | |
Free Cash Flow |
194.44 | 48.67 | 292.04 | 271.15 | |
Working Capital |
2,584.31 | 2,869.83 | 3,107.66 | 3,049.66 | |
Capital Expenditures |
(23.29) | (21.83) | (34.68) | (69.83) | |
Net Current Asset Value |
(126.49) | 165.14 | 415.52 | 721.84 | |
EV/EBIT |
101.04 | 55.80 | 37.93 | 31.14 | |
Capex to Sales |
0.02 | 0.02 | 0.03 | 0.05 | |
Price to Operating Income |
104.83 | 58.46 | 40.23 | 33.78 | |
| Other line items | |||||
Average Receivables |
591.44 | 651.00 | 739.93 | 1,024.84 | |
Average Payables |
102.07 | 112.01 | 105.20 | 126.50 | |
Average Inventory |
80.61 | 74.80 | 84.40 | 90.65 | |
Average Assets |
4,603.16 | 4,671.68 | 5,062.39 | 6,423.17 | |
Average Common Equity |
428.13 | 595.41 | 802.35 | 1,918.87 |
Columns are period end dates · fundamentals updated 5 Nov 2026